Synairgen (LON:SNG) Stock Price Down 9.5% – Here’s Why

Shares of Synairgen plc (LON:SNG) were down 9.5% on Monday . The stock traded as low as GBX 1.81 ($0.02) and last traded at GBX 1.81 ($0.02). Approximately 129,056 shares traded hands during mid-day trading, a decline of 91% from the average daily volume of 1,508,068 shares. The stock had previously closed at GBX 2 ($0.03).

Synairgen Trading Down 9.5 %

The company has a 50-day moving average price of GBX 2.32 and a two-hundred day moving average price of GBX 3.51. The stock has a market capitalization of £17.71 million, a P/E ratio of -1.09 and a beta of -2.23.

About Synairgen

Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on lung viral defence in asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease.

Synairgen is conducting a double blind, placebo-controlled clinical trial in COVID-19 patients (SG016).